0001628280-26-008002
SEC filingT. Rowe Price Group, Inc. (TROW) reported strong FY 2025 financial results with net revenues of $7.31B and net income attributable to T. Rowe Price Group of $2.09B. Net operating income reached $2.19B on total operating expenses of $5.13B, driven by compensation and related costs ($2.87B), technology and facility costs ($723.6M), and restructuring charge ($177.3M). Non-operating income contributed $686.7M, including net gains on investments ($464.9M) and consolidated investment products ($219.9M), leading to income before taxes of $2.88B and net income of $2.21B after $667.2M tax provision. Basic and diluted EPS both stood at $9 per share. Balance sheet showed total assets of $14.34B, with cash and equivalents at $3.38B, investments $3.33B, and stockholders' equity attributable to TROW at $10.86B. Operating cash flow was $1.75B, investing activities provided $230.3M, while financing used $1.28B mainly for $620.9M stock repurchases and $1.14B dividends. Net change in cash was $704.4M, ending at $1.87B (note: balance sheet cash $3.38B includes consolidated products). These results reflect robust profitability and capital returns amid investment gains, positioning TROW for sustained shareholder value.
T. Rowe Price Group, Inc. delivered solid FY 2025 results ending December 31, 2025. Net revenues totaled $7.31B, yielding net operating income of $2.19B after $5.13B in operating expenses. Key expenses included compensation and related costs at $2.87B (56% of total), technology, occupancy, and facility costs $723.6M, distribution and servicing $383.5M, and one-time items like $177.3M restructuring charge and $111.3M acquisition-related amortization. Non-operating income added $686.7M from net gains on investments ($464.9M) and consolidated products ($219.9M), driving income before taxes to $2.88B. After $667.2M provision for income taxes, net income was $2.21B, with $121.2M attributable to redeemable non-controlling interests, leaving $2.09B for TROW shareholders. Basic and diluted EPS both at $9. Total assets grew to $14.34B, supported by $3.38B cash equivalents and $3.33B investments. Stockholders' equity attributable to TROW was $10.86B, with retained earnings $10.87B. No prior year figures disclosed for direct YoY comparison. (152 words)
Net revenues reported at $7.31B for FY 2025. No breakdown provided for investment advisory fees, performance-based fees, or administrative fees—all marked N/A in XBRL. No segment reporting or geographic mix disclosed in the filing. Growth drivers not specified in available data. Revenue less operating expenses produced $2.19B net operating income. Non-operating items significantly boosted results with $686.7M total, primarily from investment gains. Filing lacks MD&A details on revenue composition or client flows. (98 words)
Operating margin calculated as net operating income $2.19B on net revenues $7.31B, approximately 30%. No gross profit or gross margin disclosed. Profitability supported by non-operating gains adding ~9% to pre-tax income. Cost structure showed compensation dominating at $2.87B (56% of opex), with technology/facilities $723.6M (14%), G&A $441.9M (9%), and special items $288.6M (6% including restructuring). No prior period margins for trend analysis. Effective tax rate ~23% ($667.2M on $2.88B pre-tax). EPS stable at $9 basic/diluted. (102 words)
Net cash from operating activities $1.75B, adjusted from $2.21B net income via $405.8M depreciation/amortization, $216.9M stock comp, offset by $452.4M investment gains and $1.00B change in consolidated product securities. Investing provided $230.3M, aided by $769.1M dispositions of sponsored products vs. $274.2M capex. Financing used $1.28B for $620.9M stock repurchases, $1.14B dividends, partially offset by $543.2M redeemable NCI subscriptions. Net cash increase $704.4M; ending cash $1.87B (balance sheet cash/equivalents $3.38B includes consolidated). Total liabilities $2.29B, no debt noted; equity $10.86B attributable to TROW. Liquidity strong. (128 words)
No management guidance, strategic priorities, or risk factors explicitly disclosed in the provided filing excerpt. Forward-looking statements absent from XBRL data and document content. Investors should review full 10-K for MD&A outlook, if available. (42 words)